Overview

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Status:
Recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Daiichi Sankyo, Inc.